- Home
- CRON vs CTY Comparison
CRON vs CTY Comparison
Compare CRON & CTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRON | CTY |
|---|---|---|
| Founded | N/A | 2023 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | CRON | CTY |
|---|---|---|
| Price | $3.29 | $20.75 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.68 | N/A |
| AVG Volume (30 Days) | ★ 775.5K | 188.2K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $146,587,000.00 | N/A |
| Revenue This Year | $50.41 | N/A |
| Revenue Next Year | $29.48 | N/A |
| P/E Ratio | $28.04 | ★ N/A |
| Revenue Growth | ★ 24.63 | N/A |
| 52 Week Low | $2.28 | $20.03 |
| 52 Week High | $3.61 | $22.34 |
Technical Indicators
Market Signals| Indicator | CRON | CTY |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 48.93 |
| Support Level | $3.12 | N/A |
| Resistance Level | $3.46 | N/A |
| Average True Range (ATR) | 0.10 | 1.09 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 43.55 | 29.31 |
Price Performance
Historical ComparisonAbout CRON Cronos Group Inc.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
About CTY City Therapeutics Inc. Common Stock
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.